Page 2 - Access Consortium News Today

/PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

We are producing guidance and information for industry, healthcare professionals and patients covering the coronavirus (COVID-19) outbreak.

Faricimab, a new medicine for people with the progressive eye diseases wet age-related macular degeneration (wet AMD) and visual impairment due to diabetic macular oedema (DMO), has been approved by the Medicines and Healthcare products Regulatory Ag

CAMBRIDGE, Mass., April 26, 2022 /PRNewswire/ -- Vedere Bio II, Inc., a company developing transformative, next-generation therapies for vision re...

/PRNewswire/ -- Vedere Bio II, Inc., a company developing transformative, next-generation therapies for vision restoration and preservation, today announced...

Cervical cancer is one of the most common cancers affecting women worldwide. Low-income economies in Asia-Pacific should improve access to prevention and treatment to manage this preventable disease.

Since our last update in April 2021, there have been many developments regarding biosimilars in Canada (approvals, pending submissions, litigation, regulatory and market access). ...

ACTED Since 1993, as an international non-governmental organization, ACTED has been committed to immediate humanitarian relief to support those in urgent need and protect people’s dignity, while co-creating longer term opportunities for sustainable growth and fulfilling people’s potential. ACTED endeavors to respond to humanitarian crises and build resilience; promote inclusive and sustainable growth; co-construct effective governance and support the building of civil society worldwide by i...

Access to COVID-19 vaccines: Global approaches in a global crisis ╳ Abstract Following the extraordinarily rapid development of COVID‑19 vaccines, immunisation is underway in many OECD countries. However, demand will continue to outstrip supply for some time and currently, distribution is strongly skewed in favour of high-income countries. This both inequitable and inefficient. Directing vaccine to where need is greatest would maximise the number of lives saved and speed bringing the pandem...

LONDON (Sputnik) – COVID-19 vaccines that are modified to combat new coronavirus variants will not need to go through more time-consuming clinical studies to get...